These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 26278029

  • 1. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands.
    Cao Y, Paudel S, Zhang X, Kim KM, Cheon SH.
    Bioorg Med Chem; 2015 Sep 01; 23(17):5264-72. PubMed ID: 26278029
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y, Min C, Acharya S, Kim KM, Cheon SH.
    Bioorg Med Chem; 2016 Jan 15; 24(2):191-200. PubMed ID: 26707842
    [Abstract] [Full Text] [Related]

  • 3. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M, Donthamsetti P, Beuming T, Banala A, Duan L, Roux T, Han Y, Trinquet E, Newman AH, Javitch JA, Shi L.
    Mol Pharmacol; 2013 Dec 15; 84(6):854-64. PubMed ID: 24061855
    [Abstract] [Full Text] [Related]

  • 4. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
    Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH.
    J Med Chem; 2011 May 26; 54(10):3581-94. PubMed ID: 21495689
    [Abstract] [Full Text] [Related]

  • 5. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P, Xie B, Semeano A, Bonifazi A, Battiti FO, Newman AH, Yano H, Shi L.
    Biomolecules; 2021 Apr 13; 11(4):. PubMed ID: 33924613
    [Abstract] [Full Text] [Related]

  • 6. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, Levy B, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L.
    J Med Chem; 2012 Aug 09; 55(15):6689-99. PubMed ID: 22632094
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and evaluation of amides surrogates of dopamine D3 receptor ligands.
    Jean M, Renault J, Levoin N, Danvy D, Calmels T, Berrebi-Bertrand I, Robert P, Schwartz JC, Lecomte JM, Uriac P, Capet M.
    Bioorg Med Chem Lett; 2010 Sep 15; 20(18):5376-9. PubMed ID: 20708933
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR.
    J Med Chem; 2014 Aug 28; 57(16):7042-60. PubMed ID: 25126833
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands.
    Zhou B, Hong KH, Ji M, Cai J.
    Chem Biol Drug Des; 2018 Sep 28; 92(3):1597-1609. PubMed ID: 29710404
    [Abstract] [Full Text] [Related]

  • 10. Improving selectivity of dopamine D3 receptor ligands.
    Capet M, Calmels T, Levoin N, Danvy D, Berrebi-Bertrand I, Stark H, Schwartz JC, Lecomte JM.
    Bioorg Med Chem Lett; 2016 Feb 01; 26(3):885-888. PubMed ID: 26723530
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists.
    Cao Y, Sun N, Zhang J, Liu Z, Tang YZ, Wu Z, Kim KM, Cheon SH.
    Medchemcomm; 2018 Sep 01; 9(9):1457-1465. PubMed ID: 30288220
    [Abstract] [Full Text] [Related]

  • 12. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V.
    Expert Opin Drug Discov; 2016 Jul 01; 11(7):641-64. PubMed ID: 27135354
    [Abstract] [Full Text] [Related]

  • 13. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs).
    Reilly SW, Riad AA, Hsieh CJ, Sahlholm K, Jacome DA, Griffin S, Taylor M, Weng CC, Xu K, Kirschner N, Luedtke RR, Parry C, Malhotra S, Karanicolas J, Mach RH.
    J Med Chem; 2019 May 23; 62(10):5132-5147. PubMed ID: 31021617
    [Abstract] [Full Text] [Related]

  • 14. Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase.
    De Simone A, Russo D, Ruda GF, Micoli A, Ferraro M, Di Martino RM, Ottonello G, Summa M, Armirotti A, Bandiera T, Cavalli A, Bottegoni G.
    J Med Chem; 2017 Mar 23; 60(6):2287-2304. PubMed ID: 28182408
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and evaluation of indolebutylamines as a novel class of selective dopamine D3 receptor ligands.
    Du P, Xu L, Huang J, Yu K, Zhao R, Gao B, Jiang H, Zhao W, Zhen X, Fu W.
    Chem Biol Drug Des; 2013 Sep 23; 82(3):326-35. PubMed ID: 23663349
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands.
    Zhou B, Ji M, Cai J.
    Bioorg Chem; 2018 Apr 23; 77():125-135. PubMed ID: 29353729
    [Abstract] [Full Text] [Related]

  • 17. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes.
    Hayatshahi HS, Luedtke RR, Taylor M, Chen PJ, Blass BE, Liu J.
    J Chem Inf Model; 2021 Jun 28; 61(6):2829-2843. PubMed ID: 33988991
    [Abstract] [Full Text] [Related]

  • 18. Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands.
    Keck TM, Banala AK, Slack RD, Burzynski C, Bonifazi A, Okunola-Bakare OM, Moore M, Deschamps JR, Rais R, Slusher BS, Newman AH.
    Bioorg Med Chem; 2015 Jul 15; 23(14):4000-12. PubMed ID: 25650314
    [Abstract] [Full Text] [Related]

  • 19. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM, Bucolo C, Platania CB, Salomone S, Drago F.
    Pharmacol Ther; 2016 Sep 15; 165():164-77. PubMed ID: 27343365
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T.
    J Med Chem; 2003 Aug 28; 46(18):3822-39. PubMed ID: 12930145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.